Foundry Partners LLC cut its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 22.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 307,619 shares of the company’s stock after selling 87,556 shares during the quarter. Sanofi accounts for about 1.0% of Foundry Partners LLC’s investment portfolio, making the stock its 26th largest holding. Foundry Partners LLC’s holdings in Sanofi were worth $16,581,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in SNY. NewEdge Wealth LLC lifted its stake in Sanofi by 3.2% in the first quarter. NewEdge Wealth LLC now owns 21,390 shares of the company’s stock valued at $1,164,000 after buying an additional 656 shares during the last quarter. Avantax Advisory Services Inc. lifted its stake in Sanofi by 24.8% in the first quarter. Avantax Advisory Services Inc. now owns 29,898 shares of the company’s stock valued at $1,627,000 after buying an additional 5,948 shares during the last quarter. Hhlr Advisors LTD. bought a new stake in Sanofi in the first quarter valued at $11,194,000. Assetmark Inc. lifted its stake in Sanofi by 13.8% in the fourth quarter. Assetmark Inc. now owns 65,978 shares of the company’s stock valued at $3,195,000 after buying an additional 7,988 shares during the last quarter. Finally, Natixis Advisors L.P. lifted its stake in Sanofi by 17.8% in the first quarter. Natixis Advisors L.P. now owns 1,987,287 shares of the company’s stock valued at $108,149,000 after buying an additional 299,652 shares during the last quarter. 10.06% of the stock is currently owned by institutional investors.
Sanofi Trading Down 0.8 %
NASDAQ:SNY opened at $54.08 on Tuesday. The company has a quick ratio of 0.81, a current ratio of 1.21 and a debt-to-equity ratio of 0.20. Sanofi has a 1-year low of $36.91 and a 1-year high of $57.82. The firm has a market capitalization of $136.54 billion, a price-to-earnings ratio of 18.52, a price-to-earnings-growth ratio of 1.57 and a beta of 0.57. The stock has a fifty day simple moving average of $53.22 and a 200 day simple moving average of $53.63.
Wall Street Analyst Weigh In
SNY has been the topic of a number of recent research reports. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 29th. HSBC assumed coverage on Sanofi in a report on Friday, July 14th. They set a “buy” rating on the stock. Finally, Berenberg Bank raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $72.50.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
- Five stocks we like better than Sanofi
- How to Invest in E-Commerce: A Guide
- 2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Got Nuclear? Three Stocks To Play Energy’s Next Frontier
- Investing in Blue-Chip Stocks
- The Top 4 Utilities for Value, Yield, and Upside Potential
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.